Miragen attracts new VC funding and shows metabolic role for heart therapeutic
This article was originally published in Scrip
Executive Summary
It's been a good week for the small microRNA-focused biotechnology company Miragen Therapeutics with the announcement of $20 million in new venture capital financing and the publication of novel preclinical findings from its lead candidate MIRG-9103, which showed unexpected therapeutic value for treating metabolic disorders.